Ajanta Pharma マネジメント

マネジメント基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Yogesh Agrawal

最高経営責任者

₹216.0m

報酬総額

CEO給与比率	57.2%
CEO在任期間	16.9yrs
CEOの所有権	14.5%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	6yrs

経営陣の近況

Recent updates

CEO報酬分析

Ajanta Pharma の収益と比較して、Yogesh Agrawal の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	₹9b
Jun 30 2024	n/a	n/a	₹9b
Mar 31 2024	₹216m	₹124m	₹8b
Dec 31 2023	n/a	n/a	₹7b
Sep 30 2023	n/a	n/a	₹7b
Jun 30 2023	n/a	n/a	₹6b
Mar 31 2023	₹156m	₹112m	₹6b
Dec 31 2022	n/a	n/a	₹6b
Sep 30 2022	n/a	n/a	₹7b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹163m	₹94m	₹7b
Dec 31 2021	n/a	n/a	₹7b
Sep 30 2021	n/a	n/a	₹7b
Jun 30 2021	n/a	n/a	₹7b
Mar 31 2021	₹128m	₹75m	₹7b
Dec 31 2020	n/a	n/a	₹6b
Sep 30 2020	n/a	n/a	₹6b
Jun 30 2020	n/a	n/a	₹5b
Mar 31 2020	₹107m	₹66m	₹5b
Dec 31 2019	n/a	n/a	₹4b
Sep 30 2019	n/a	n/a	₹4b
Jun 30 2019	n/a	n/a	₹4b
Mar 31 2019	₹99m	₹61m	₹4b
Dec 31 2018	n/a	n/a	₹4b
Sep 30 2018	n/a	n/a	₹5b
Jun 30 2018	n/a	n/a	₹5b
Mar 31 2018	₹44m	₹13m	₹5b

報酬と市場: Yogeshの総報酬 ($USD 2.56M ) は、 Indian市場 ($USD 589.97K ) の同規模の企業の平均を上回っています。

報酬と収益: Yogeshの報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Yogesh Agrawal (52 yo)

16.9yrs

在職期間

₹215,960,000

報酬

Mr. Yogesh Mannalal Agrawal, M.B.A, has been Managing Director at Ajanta Pharma Ltd. since December 14, 2007. Mr. Agrawal is handling global business of Ajanta Pharma Ltd.He has handled various aspects of...

取締役

名称	ポジション	在職期間	報酬	所有権
Yogesh Agrawal	MD & Executive Director	24.6yrs	₹215.96m	14.48% ₹ 53.5b
Rajesh Agrawal	Joint MD & Director	11.6yrs	₹215.96m	14.48% ₹ 53.5b
Madhusudan Agrawal	Executive Vice Chairman of the Board	26.9yrs	₹42.04m	データなし
Ramesh Jhawar	Director of Ajanta Pharma USA Inc.	no data	₹25.50m	データなし
Mannalal Agrawal	Chairman of the Board	44.9yrs	₹777.00k	データなし
David Rasquinha	Independent Non-Executive Director	less than a year	データなし	データなし
Medha Joshi	Independent Non-Executive Director	less than a year	データなし	データなし
Sam Gioskos	Director of Ajanta Pharma Philippines Inc.	no data	データなし	データなし
Suttian Deerpaul	Director of Ajanta Pharma (Mauritius) Ltd.	no data	データなし	データなし
Vinayak Muzumdar	Director of Ajanta Pharma (Mauritius) Ltd.	no data	データなし	データなし
Rajesh Dalal	Independent Non-Executive Director	less than a year	データなし	データなし
Simi Thapar	Independent Non-Executive Director	less than a year	データなし	データなし

6.0yrs

平均在職期間

68yo

平均年齢

経験豊富なボード: 532331の取締役会は経験豊富であると考えられます ( 6年の平均在任期間)。

Ajanta Pharma マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Chief Financial Officer recently sold ₹20m worth of stock

Executive Vice President recently sold ₹5.9m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Recent updates

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q2, 2025 Results on Oct 28, 2024

Price target increased by 7.1% to ₹2,874

Chief Financial Officer recently sold ₹20m worth of stock

Executive Vice President recently sold ₹5.9m worth of stock

Price target increased by 7.6% to ₹2,664

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited to Report Q1, 2025 Results on Jul 30, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2024

Price target increased by 7.4% to ₹2,440

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,028,881 shares, representing 0.82% for INR 2,850 million.

Full year 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q4, 2024 Final Results on May 02, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024

Ajanta Pharma Limited to Report Q3, 2024 Results on Jan 31, 2024

Second quarter 2024 earnings: EPS exceeds analyst expectations

Ajanta Pharma Limited to Report Q2, 2024 Results on Oct 31, 2023

Price target increased by 10.0% to ₹1,652

First quarter 2024 earnings released: EPS: ₹16.53 (vs ₹13.63 in 1Q 2023)

Ajanta Pharma Limited to Report Q1, 2024 Results on Jul 27, 2023

Insider recently sold ₹2.1m worth of stock

Ajanta Pharma Limited, Annual General Meeting, Jul 18, 2023

Insider recently sold ₹1.9m worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q3, 2023 Results on Feb 01, 2023

Insufficient new directors

Ajanta Pharma Limited Approves Interim Dividend

Second quarter 2023 earnings: EPS misses analyst expectations

Ajanta Pharma Limited to Report Q2, 2023 Results on Nov 03, 2022

Price target increased to ₹1,574

US FDA Announces Inspection of Pharma Limited Dahej Facility

Ajanta Pharma Limited to Report Q1, 2023 Results on Jul 28, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited, Annual General Meeting, Aug 04, 2022

Price target decreased to ₹2,335

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Ajanta Pharma Limited to Report Q4, 2022 Results on May 10, 2022

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Ajanta Pharma Limited (NSEI:AJANTPHARM) announces an Equity Buyback for 1,120,000 shares, representing 1.29% for INR 2,856 million.

Insider recently sold ₹8.1m worth of stock

Insider recently sold ₹1.1m worth of stock

Upcoming dividend of ₹9.50 per share

Second quarter 2022 earnings released: EPS ₹22.64 (vs ₹19.51 in 2Q 2021)

Director of Ajanta Pharma USA Inc. recently sold ₹6.9m worth of stock

Price target increased to ₹2,394

First quarter 2022 earnings released: EPS ₹20.08 (vs ₹16.93 in 1Q 2021)

Price target increased to ₹2,260

Price target increased to ₹2,139

Insider recently sold ₹2.1m worth of stock

Full year 2021 earnings released: EPS ₹75.09 (vs ₹53.60 in FY 2020)

Insider recently sold ₹1.9m worth of stock

Full year 2021 earnings released: EPS ₹75.09 (vs ₹53.60 in FY 2020)

New 90-day high: ₹1,831

Insider recently sold ₹14m worth of stock

Revenue and earnings beat expectations

Price target raised to ₹1,857

Third quarter 2021 earnings released: EPS ₹20.41 (vs ₹12.33 in 3Q 2020)

Ajanta Pharma Limited to Report Q3, 2021 Results on Feb 02, 2021

Insider recently sold ₹650k worth of stock

New 90-day high: ₹1,704

Insider recently sold ₹798k worth of stock

Insider recently sold ₹818k worth of stock

New 90-day high: ₹1,678

Insider recently bought ₹3.8m worth of stock

Revenue and earnings beat expectations

マネジメント基準チェック /14